Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seventeen research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, fourteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $23.14.
CMPS has been the subject of a number of research reports. B. Riley Financial raised their target price on Compass Pathways from $17.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Jefferies Financial Group reissued a "buy" rating on shares of Compass Pathways in a research report on Monday, November 9th. BTIG Research reissued a "buy" rating and issued a $25.00 price objective on shares of Compass Pathways in a research note on Tuesday, November 3rd. Morgan Stanley raised their price objective on shares of Compass Pathways from $17.00 to $18.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Pathways in a research report on Thursday, October 15th.
View Our Latest Stock Analysis on Compass Pathways
Hedge Funds Weigh In On Compass Pathways
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC bought a new position in Compass Pathways during the 1st quarter valued at about $1,106,000. Seven Fleet Capital Management LP raised its position in Compass Pathways by 295.1% during the 1st quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company's stock valued at $874,000 after purchasing an additional 118,021 shares in the last quarter. Orbimed Advisors LLC purchased a new position in shares of Compass Pathways during the first quarter valued at $6,363,000. Eversept Partners LP bought a new stake in shares of Compass Pathways in the first quarter valued at about $3,749,000. Finally, Diversify Advisory Services LLC purchased a new position in Compass Pathways during the 3rd quarter valued at about $1,503,000. Institutional investors own 46.19% of the company's stock.
Compass Pathways Stock Performance
Compass Pathways stock opened at $8.65 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.50 and a quick ratio of 1.50. Compass Pathways has a 12 month low of $4.88 and a 12 month high of $15.87. The stock's 50-day moving average is $11.42 and its 200-day moving average is $10.49. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -2.48 and a beta of 2.43.
Compass Pathways (NASDAQ:CMPS - Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.08. Equities analysts anticipate that Compass Pathways will post -0.78 earnings per share for the current year.
Compass Pathways Company Profile
(
Get Free Report)
Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Compass Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Pathways wasn't on the list.
While Compass Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.